PerSeptive signs distribution deal with Boehringer Mannheim:
This article was originally published in Clinica
Boehringer Mannheim (Germany) is to distribute PerSeptive Biosystem's (US) Poros chromatography columns worldwide. Under the terms of the deal Boehringer has agreed to purchase $2 million worth of PerSeptive common stock at a price of $12.69 and has an option to acquire a further $1 million at the same price over the next two years.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.